PCR Technologies Market to Reach $18.3 Billion by 2027

The global PCR technologies Market is expected to reach USD 18.3 billion by 2027 from an estimated USD 12.5 billion in 2022, at a CAGR of 8.0%

The global PCR technologies Market is expected to reach USD 18.3 billion by 2027 from an estimated USD 12.5 billion in 2022, at a CAGR of 8.0% from 2022 to 2027.

Polymerase chain reaction (PCR) is a well-established technique used for the in vitro amplification of a given nucleotide (such as DNA). This technique is used to prepare multiple copies of a gene and to synthesize a large number of DNA molecules from a given DNA sample. This is done by separating the two strands of the DNA, marking its location with a primer, and using a DNA polymerase enzyme to synthesize and assemble a copy of the gene alongside a template.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96291811

PCR Technologies Market by Technique (Conventional, qPCR, dPCR), Product (Instrument, Reagents, Software), Application (Genotyping, Sequencing, Gene Expression, Diagnostics), End User (Academia, Pharma-Biotech, Applied) – Global Forecast to 2027

Growth in this market is largely driven by factors such as the rising incidence of target infectious diseases and genetic disorders, continuous advancements in PCR technologies and increasing investments.

The demand for early disease diagnosis and treatment has driven the R&D in developing genetic technologies and product development. This rise in R&D activity is supported by an increase in investments and the availability of funds and grants. For instance, in March 2018, vc (WGGC) and the Universities of Cologne, Bonn, and Düsseldorf (Germany), received ~USD 5.98 million (EUR 5.3 million) for a joint competence center from the German Research Foundation (DFG).

Government and federal agencies across the globe are recognizing the role of qPCR and dPCR products (such as instruments, reagents, and software) in genomics-based research. In the last decade, the qPCR and dPCR market has witnessed several funding initiatives by government and private agencies to support genomic research. In October 2020, Visby Medical (US), an infectious disease diagnostic company, received Phase 2 funding from the National Institutes of Health (NIH) as part of its Rapid Acceleration of Diagnostics (RADx) initiative. In addition, Centre d’innovation Génome Québec et Université McGill (Canada) received ~USD 10 million in funding from federal and provincial investments on February 2019. The funding will be utilized for projects in the field of bioinformatics, epigenomics, and precision medicine, among other fields (Source: McGill University, Canada). These initiatives are aimed at conducting medical genomics-based studies in personalized medicine, including PCR-based disease diagnosis and treatment.

Thus, with the growing availability of financial support for sustaining R&D in disease-targeted genomics research activities, the demand for PCR products is expected to increase in the coming years.

On the other hand, issues related to high instrument costs of dPCR and the limitations of PCR technologies are expected to restrict the market growth to a certain extent in the coming years.

dPCR instruments integrates scientific technologies such as PCR, microfluidics, and nanofabrication, to conduct a typical PCR analysis. These instruments are small, however, their development requires big investments and extensive scientific validation on a nanoscale level. As of 2022, the average price of a dPCR instrument in the US is reported to be USD 55,000–120,000. Such high prices have resulted in the subdued adoption of dPCR instruments among price-sensitive end users. Moreover, the dPCR instruments are expensive compared to qPCR instruments (~USD 90,000).

Due to the preference for cheaper genomic techniques (such as gel electrophoresis and traditional PCR), the demand for premium-priced dPCR instruments and reagents is restricted, especially among researchers and small CROs and pharmaceutical & biotechnology companies.

On the basis of product, the global PCR technologies market is broadly classified into instruments, reagents and consumables, and software and services. In 2021, the reagents and consumables segment accounted for the largest share of the PCR technologies market. This is mainly due to the expanding applications of dPCR, increasing number of dPCR-based analytical procedures among institutional researchers (such as CROs and pharma-biotech companies), and the rising availability of novel dPCR reagents worldwide. Additionally, the expansion of the application base of the dPCR technology in genetic/molecular research, clinical diagnosis, and forensics is expected to result in the commercialization of novel dPCR reagents.